Abstract:The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.

Hepatic Stellate Cell: A Double-Edged Sword in the Liver

Hepatic stellate cells: unique characteristics in cell biology and phenotype

Effects of hepatic stellate cells in hepatic diseases

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis

[Update on isolation and functional research of hepatic stellate cells]

[Mechanism of Hepatic Stellate Cell Migration During Liver Fibrosis].

Immunological characteristics of hepatic stellate cells

Plasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology

Migration Of Hepatic Stellate Cells In Fibrotic Microenvironment Of Diseased Liver Model

Hepatic stellate cells: a target for the treatment of liver fibrosis

Hepatic Stellate Cell Behavior during Resolution of Liver Injury

Modulation of hepatic stellate cells and reversibility of hepatic fibrosis.

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

The evidence-based multifaceted roles of hepatic stellate cells in liver diseases: A concise review

Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis

The Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells

Cytokine Receptors and Signaling in Hepatic Stellate Cells

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

Hepatic stellate cells in inflammation-fibrosis-carcinoma axis.

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy